Arrivent Biopharma, Common Stock Buy Hold or Sell Recommendation
| AVBP Stock | 21.00 0.75 3.45% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding ArriVent BioPharma, Common is 'Sell'. A buy or sell recommendation provided by Macroaxis is an automated analysis based on historical performance and your stated risk tolerance. It serves as guidance on whether to purchase or sell ArriVent BioPharma, Common within the specified time frame.
Check out ArriVent BioPharma, Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as ArriVent and provide practical buy, sell, or hold advice based on investors' constraints. ArriVent BioPharma, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
ArriVent |
Execute ArriVent BioPharma, Buy or Sell Advice
The ArriVent recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on ArriVent BioPharma, Common. Macroaxis does not own or have any residual interests in ArriVent BioPharma, Common or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute ArriVent BioPharma,'s advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
ArriVent BioPharma, Trading Alerts and Improvement Suggestions
| ArriVent BioPharma, generated a negative expected return over the last 90 days | |
| ArriVent BioPharma, has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (80.49 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ArriVent BioPharma, generates negative cash flow from operations | |
| ArriVent BioPharma, has a poor financial position based on the latest SEC disclosures | |
| Over 85.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: ArriVent BioPharma Reports Full Year 2024 Financial Results |
ArriVent BioPharma, current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ArriVent analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ArriVent analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
ArriVent BioPharma, Returns Distribution Density
The distribution of ArriVent BioPharma,'s historical returns is an attempt to chart the uncertainty of ArriVent BioPharma,'s future price movements. The chart of the probability distribution of ArriVent BioPharma, daily returns describes the distribution of returns around its average expected value. We use ArriVent BioPharma, Common price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of ArriVent BioPharma, returns is essential to provide solid investment advice for ArriVent BioPharma,.
| Mean Return | -0.46 | Value At Risk | -6.39 | Potential Upside | 3.57 | Standard Deviation | 2.93 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of ArriVent BioPharma, historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
ArriVent BioPharma, Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to ArriVent BioPharma, or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that ArriVent BioPharma,'s price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a ArriVent stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.36 | |
β | Beta against Dow Jones | 1.00 | |
σ | Overall volatility | 2.87 | |
Ir | Information ratio | -0.12 |
ArriVent BioPharma, Volatility Alert
ArriVent BioPharma, Common exhibits very low volatility with skewness of -0.45 and kurtosis of -0.28. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure ArriVent BioPharma,'s stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact ArriVent BioPharma,'s stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.ArriVent BioPharma, Fundamentals Vs Peers
Comparing ArriVent BioPharma,'s fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze ArriVent BioPharma,'s direct or indirect competition across all of the common fundamentals between ArriVent BioPharma, and the related equities. This way, we can detect undervalued stocks with similar characteristics as ArriVent BioPharma, or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of ArriVent BioPharma,'s fundamental indicators could also be used in its relative valuation, which is a method of valuing ArriVent BioPharma, by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare ArriVent BioPharma, to competition |
| Fundamentals | ArriVent BioPharma, | Peer Average |
| Return On Equity | -0.39 | -0.31 |
| Return On Asset | -0.27 | -0.14 |
| Current Valuation | 495.65 M | 16.62 B |
| Shares Outstanding | 34.02 M | 571.82 M |
| Shares Owned By Insiders | 9.71 % | 10.09 % |
| Shares Owned By Institutions | 84.55 % | 39.21 % |
| Number Of Shares Shorted | 4.19 M | 4.71 M |
| Price To Book | 2.77 X | 9.51 X |
| EBITDA | (74.59 M) | 3.9 B |
| Net Income | (80.49 M) | 570.98 M |
| Total Debt | 176 K | 5.32 B |
| Book Value Per Share | 7.64 X | 1.93 K |
| Cash Flow From Operations | (70.21 M) | 971.22 M |
| Short Ratio | 22.54 X | 4.00 X |
| Earnings Per Share | (2.56) X | 3.12 X |
| Target Price | 39.67 | |
| Number Of Employees | 52 | 18.84 K |
| Market Capitalization | 714.34 M | 19.03 B |
| Total Asset | 274.94 M | 29.47 B |
| Retained Earnings | (238.33 M) | 9.33 B |
| Working Capital | 209.71 M | 1.48 B |
| Net Asset | 274.94 M |
Note: Acquisition by Hillhouse Investment Management, Ltd. of 555555 shares of ArriVent BioPharma, at 18.0 subject to Rule 16b-3 [view details]
ArriVent BioPharma, Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as ArriVent . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About ArriVent BioPharma, Buy or Sell Advice
When is the right time to buy or sell ArriVent BioPharma, Common? Buying financial instruments such as ArriVent Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having ArriVent BioPharma, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Macroaxis Index Thematic Idea Now
Macroaxis Index
An experimental equal-weighted index theme of selected equities generated based on Macroaxis rating and scoring system. The Macroaxis Index theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Macroaxis Index Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma,'s price analysis, check to measure ArriVent BioPharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma, is operating at the current time. Most of ArriVent BioPharma,'s value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma,'s price. Additionally, you may evaluate how the addition of ArriVent BioPharma, to your portfolios can decrease your overall portfolio volatility.